On schizophrenia and new generation drugs (multiple letters) [1]

Neuropsychopharmacology

Volumn 22, Issue 6, 2000, Pages 660-661

  Carpenter, William T ^a   Conley, Robert ^a   Kirkpatrick, Brian ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE;

DRUG EFFICACY; DRUG RESPONSE; HUMAN; LETTER; NEGATIVE SYNDROME; OUTPATIENT; PRIORITY JOURNAL; SCHIZOPHRENIA; SYMPTOM;

ANTIPSYCHOTIC AGENTS; HUMANS; SCHIZOPHRENIA;

EID: 0034090750     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0893-133X(99)00155-4     Document Type: Article

References (23)

1. R.W. Buchanan A. Breier B. Kirkpatrick P. Ball W.T. Carpenter Jr Positive and negative symptom response to clozapine in schizophrenic patients with and without the deficit syndrome Am J Psychiatry 155 6 1998 751 760
2. W.T. Carpenter Serotonin-dopamine antagonists and treatment of negative symptoms J Clin Psychopharmacol 15 Suppl 1 1995 30S 35S
3. W.T. Carpenter C. Arango R.W. Buchanan B. Kirkpatrick Deficit psychopathology and a paradigm shift in schizophrenia research Biol Psychiatry 46 1999 352 360
4. W.T. Carpenter R.W. Buchanan B. Kirkpatrick C. Tamminga F. Wood Strong inference, theory testing, and the neuroanatomy of schizophrenia Arch Gen Psychiatry 50 1993 825 831
5. W.T. Carpenter R.R. Conley R.W. Buchanan A. Breier C.A. Tamminga Patient response and resource management Another view of clozapine treatment of schizophrenia Am J Psychiatry 152 1995 827 832
6. W.T. Carpenter D.W. Heinrichs A.M.I. Wagman Deficit and non-deficit forms of schizophrenia The concept Am J Psychiatry 145 1988 578 583
7. R. Conley C. Richardson D. Kent C. Gounaris S. Zaremba Clozapine responses varies in deficit vs. non-deficit schizophrenic subjects Biol Psychiatry 35 9 1994 746
8. R.R. Conley C.A. Tamminga J.J. Bartko C. Richardson M. Peszke J. Lingle J. Hegerty R. Love C. Gounaris S. Zaremba Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia Am J Psychiatry 155 7 1998 914 920
9. D.C. Goff G. Tsai J. Levitt E. Amico D. Manoach D.A. Schoenfeld D.L. Hayden R. McCarley J.T. Coyle A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia Arch Gen Psychiatry 56 1999 21 27
10. D.C. Goff G. Tsai D.S. Manoach J.T. Coyle Dose-finding trial of d-cycloserine added to neuroleptics for negative symptoms in schizophrenia Am J Psychiatry 152 1995 1213 1215
11. U. Heresco-Levy D.C. Javitt M. Ermilov C. Mordel A. Horowitz D. Kelly Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia Br J Psychiatry 169 1996 610 617
12. U. Heresco-Levy D.C. Javitt M. Ermilov C. Mordel G. Siliop M. Lichenstein Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia Arch Gen Psychiatry 56 1999 29 36
13. D.C. Javitt I. Zylberman S.R. Zukin U. Heresco-Levy J.-P. Lindenmayer Amelioration of negative symptoms in schizophrenia by glycine Am J Psychiatry 151 1994 1234 1236
14. E. Kraepelin Dementia Praecox and Paraphrenia 1971 Robert E Krieger New York
15. J.A. Lieberman A.Z. Safferman S. Pollack S. Szymanski C. Johns A. Howard M. Kronig P. Bookstein J.M. Kane Clinical effects of clozapine in chronic schizophrenia Response to treatment and predictors of outcome Am J Psychiatry 151 12 1994 1744 1752
16. H.Y. Meltzer The role of serotonin in antipsychotic drug action Neuropsychopharmacology 21 25 1999 106S 115S
17. H.J. Moller H. Muller R.L. Borison N.R. Schooler G. Chouinard A path-analytical approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenic patients. A re-evaluation of the North American risperidone study Eur Arch Psychiatry Clin Neurosci 245 1 1995 45 49
18. R. Rosenheck L. Dunn M. Peszke J. Cramer W. Xu J. Thomas D. Charney Impact of clozapine on negative symptoms and on the deficit syndrome in refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia Am J Psychiatry 156 1 1999 88 93
19. N. Schooler S. Marder J. Kane K.N.R. Chengappa W. Wirshing D. Umbricht H. Parepally D. Wirshing G. Petrides Clozapine and risperidone A 29-week randomized clinical trial Schizophr Res 36 1–3 1999 296
20. R. Tandon R. Goldman J.R. DeQuardo M. Goldman M. Perez M. Jibson Positive and negative symptoms co-vary during clozapine treatment in schizophrenia J Psychiatric Res 27 1993 341 347
21. G.D. Tollefson T.M. Sanger Negative symptoms A path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine Am J Psychiatry 154 4 1997 466 474
22. G. Tsai P. Yang L.-C. Chung N. Lange J.T. Coyle D-serine added to antipsychotics for the treatment of schizophrenia Biol Psychiatry 44 1998 1081 1089
23. K. Wahlbeck M. Cheine A. Essali C. Adams Evidence of clozapine's effectiveness in schizophrenia A systematic review and meta-analysis of randomized trials Am J Psychiatry 156 7 1999 990 999